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Current restrictions for human cell-based therapies have been related to technological limitations with re-
gards to cellular proliferation capacity, maintenance of differentiated phenotype for primary human cell
culture, and transmission of communicable diseases. We have seen that cultured primary fetal cells from
one organ donation could possibly meet the exigent and stringent technical aspects for development of
therapeutic products. We could develop a master cell bank (MCB) of 50 homogenous ampoules of 4–5
million cells each from one fetal organ donation (skin) in short periods of time compared to other primary
cell types. Safety tests were performed at all stages of the cell banking. MCB ampoules could create a
working cell bank to be used for clinical or research use. Monolayer culture of fetal skin cells had a life
span of 12–17 passages, and independent cultures obtained from the same organ donation were consistent
for protein concentration (with 1.4-fold maximal difference between cultures) as well as gene expression of
MMP-14, MMP-3, TIMP-3, and VEGF (1.4-, 1.9-, 2.1-, and 1.4-fold maximal difference between cultures,
respectively). Cell cultures derived from four independent fetal skin donations were consistent for cell
growth, protein concentration, and gene expression of MDK, PTN, TGF-β1, and OPG. As it is the intention
that banked primary fetal cells can profit from the potential treatment of hundreds of thousands of patients
with only one organ donation, it is imperative to show consistency, tracability, and safety of the process,
including donor tissue selection, cell banking, cell testing, and growth of cells in upscaling for the prepara-
tion of cell transplantation.
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INTRODUCTION theses, including artificial hips, knees, intervertebral
discs, and teeth. However, long-term survival of im-
plants is limited due to mechanical mismatch betweenEstablishment of cell banks is a crucial step in the
process of many vaccines, medicinal products, or tissue- the implant and tissue (16,19,24).
Within this context, TEP can provide biological sub-engineering products (TEP). The need for TEP is largely
increasing as the population ages. Regeneration capacity stitutes to replace, restore, or repair damaged tissue in a
wide range of areas (1,2,4,12,18,27,29). Skin, however,of mammalian tissue gradually disappears from the em-
bryo to adult state, where healing response leads to the is the most active subject of research and clinical appli-
cation (18). The design of TEP includes a biologicallyformation of fibrosed tissue and loss of organ function.
One solution has been to replace deficient organs by active substance and a delivery system. Scaffolds pro-
vide a three-dimensional support for cell attachment,grafts. Whereas transplantations of kidneys, bone mar-
row, liver, lungs, and heart are well-established proce- proliferation, and differentiation as well as for new tis-
sue formation. Combination of material, three-dimen-dures, the demand for organ transplantation cannot be
fulfilled due to limited availability of graft and immuno- sion architecture, and degradation rates allow the con-
ception of various scaffolds customized to specificcompatibility problems. On the other hand, tissues with
high mechanical functions have been replaced with pros- applications. Regarding cell-based TEP for skin, the
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choice of cell type is of primary importance. Cells used no mechanical properties. Human fetal bone cells were
shown to have high proliferation and differentiation abil-for TEP need to be readily expanded in vitro and to
retain biological activity for restoring and maintaining ity and could be used as a source of cells for TEP for
bone (23,26). Although application of fetal cells in TEPorgan functions. Autologous cells are usually preferred
as they avoid rejection and treatment with immunosup- is broad, high levels of safety and consistency in cell
banking are common features necessary for their devel-pressive drugs, but these are limited to the patient and
the limitations to this technique reside in the in vitro opment in clinics. Hence, in this article we present the
criteria for the establishment of a fetal skin cell bankexpansion of the cells (7).
Biopsy from severely burned adjacent skin can be of with emphasis on the consistency and safety aspects
necessary for preclinical trials.poor quality and/or cannot yield enough cells for in vitro
expansion (13). Additionally, these biopsies on the pa-
MATERIALS AND METHODStient create a second surgical wound, which is generally
Fetal Skin Tissuepainful and slow healing. Allogenic cells (not from the
same individual) have been investigated as an alternative For this study, we have acquired four organ donations
of fetal skin with written consent from each mother do-source of cells coming from human or animal (xenoge-
neic) sources. Again, skin is one main area of allogenic nor as approved by the University Hospital Ethics Com-
mittee. Organ donations ranged from 13 to 17 weeks ofTEP (9,32), but similar to autologous cell transplanta-
tions, in vitro expansion and maintenance of a differenti- gestation (FS1, 14 weeks female; FS2, 17 weeks female;
FS3, 13 weeks male; FS4, 14 weeks male), and a 1–4-ated state are major limits (18,34).
Stem cells have garnered the hopes of scientists be- cm2 biopsy from the abdominal region was excised. At
this stage, observations concerning the tissue receivedcause they have high self-renewal capacity and can gen-
erate multiple cell lineages (29). They can be isolated were noted (color, size, consistence) and representative
samples were taken and examined microscopically tonot only from bone marrow but also from many tissues,
such as amniotic fluid, brain, skin, heart, kidneys, and confirm that the tissue was acceptable for subsequent
expansion of cells. Tissue was also sent for pathologicalliver. Although widely distributed, stem cells represent
only a small fraction of a tissue cell population, which assessment.
For each organ donation, a specific record was pre-requires an extensive in vitro expansion step. Another
source of stem cells is blastocytes. These embryonic pared in relation to the donor and to the fetal tissue ob-
tained. Relevant details relating to the health of thestem cells (ESC) can be isolated from early-stage em-
bryo and present the advantage of being pluripotent, un- mother who donated the fetal tissue were specifically
recorded as part of the record for the original tissue. Thelike those from adult stem cells, which can differentiate
into a restricted number of cell lineages. patient name was not recorded; the patient was given a
reference number for traceability following Good Clini-Cultures of stem cells are technically very demand-
ing. Maintenance and expansion of adult stem cells in cal Practice guidelines. The mother donors were tested
for infectious diseases (status of the donor for HIV,an undifferentiated state require the addition of many
specific growth factors (1), and so far culture of ESC HBV, and HCV) at the time of tissue donation and again
3 months after to ensure negative sero-conversion (Fig.has not been possible without feeder layers (which are
usually formed by animal cells), which is in some part 1, donor testing). Testing and antibodies used were as
follows: HBsAg-Cobas Core HbsAgII EIA (Hoffmann-responsible for the inconsistent colony cell growth (20).
The necessity to use exogenous growth factors as well La Roche AG); anti-HIV-1/HIV-2 (Hoffmann-La Roche
AG); Cobas Core anti-HIV-1/HIV-2 EIA DAGS IIas animal products is a limiting factor for the scale-up
of stem cell cultures for clinical applications. Unlike (Hoffmann-La Roche AG); anti HCV-Cobas Core anti-
HCV EIA (Hoffmann-La Roche AG); AXSym anti-stem cells, fetal cells are differentiated cells with high
expansion, regeneration, and low immunogenicity prop- HCV EIA, version 3.0 (Abbott Diagnostika); PCR-
HCV-Cobas Amplicor, version 2.0 (Hoffmann-Laerties (2,4). They can be isolated from fetal tissues,
which follow embryonic stage at 9 weeks of develop- Roche AG); Treponema pallidum: Serodia-TP.PA (Fuji-
rebio, Almedica AG); anti-CMV-Vidas CMV IgGment.
Biological bandages composed of fetal skin fibro- (BioMe´rieux SA); ETI-CYTOK-M reverse (Sorin Diag-
nostics S.r.L); Toxoplasma gondii-Toxo-Screen DAblasts showed convincing results in regenerating skin in
wounds and second and third degree burned children (IgG) and Toxo-ISAGA (IgM) (BioMe´rieux SA).
For the tissue, information concerning the age of the(8,17). Development of fetal cell treatments shows
promising results in other areas, such as in orthopedics. fetus, date, time, and place of acquirement were re-
corded. Types and amounts of tissue received and intoIn response to injury, bone yields a fibrosis tissue with
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how many containers were also recorded. The containers Although the donor was obviously a human source,
isoenzyme testing to show Caucasian human origin waswere then labeled with the identification code before
transfer to the laboratory. Details of the medium into necessary for documentation. Other tests were sterility,
mycoplasma, and retroviral reverse transcriptase activitywhich the tissues were collected (DMEM, Gibco), to-
gether with supplier, batch number, and certificates were (FPERT assay). Examinations for viruses, virus-like par-
ticles, mycoplasmas, fungi, yeasts, and bacteria wereattached to the record. Sterility and microbiological test-
ing of the media were performed and specific containers done with a minimum profile of 200 cells with quantita-
tive transmission electron microscopy. In vitro testing ofwith medium were provided to the medical doctor re-
sponsible and kept in a designated refrigerator. Prior to picornovirus, orthomyxovirus, pramyxovirus, herpesvi-
rus, adenovirus, and reovirus was accomplished withtransfer to the laboratory, the tissue was stored for less
than half a day in the designated refrigerator, under lock several control cell lines. In vivo virus testing was com-
pleted using suckling mice, adult mice, guinea pigs, andand key, that was accessed only by the medical doctor.
embryonated eggs. Human virus detection was screened
Processing of the Fetal Skin Tissue using Q-PCR for all of the following viruses: HepB,
HepC, HIV-1, HIV-2, HTLV-1, HTLV-2, HHV-6,Specific cell culture from biopsy material has been
previously described elsewhere (8,17) and is repre- HHV-7, HHV-8, EBV, hCMV, SV40. B19 parovirus
was also screened with Q-PCR (Fig. 1, MCB testing).sented, in part, in Figure 1. Briefly, fetal skin biopsies
were cleaned of adherent tissue, washed three times for All of the extensive tests were accomplished and vali-
dated in the GMP facilities of Bioreliance (Glasgow,15 min each in phosphate-buffered saline (PBS: NaCl
6.80 g/L, Na2HPO4 1.48 g/L, KH2PO4 0.43 g/L), dis- Scotland). Safety testing of the working cell bank
(WCB) for preclinical and research projects can then besected, and put into culture in tissue culture grade plates
(60 cm, Falcon). Once the adherent cells reached 80% somewhat limited compared to the MCB safety testing
because each MCB ampoule results in a full WCB (Fig.confluence, they were trypsinized (EDTA and trypsin
solution, Gibco), amplified, and ampoules of cells in 1 1, WCB testing). Safety testing for laboratory research-
developed cell banks need to be continually controlledml of freezing medium (50% DMEM, 40% FCS, 10%
DMSO) were stored in liquid nitrogen. Cell banks were for mycoplasma and bacterial contamination.
stored in the vapor phase of alarm-fitted (to assure suffi-
Consistency of Processing of Tissuecient liquid nitrogen) liquid nitrogen storage vessels
(Carbagas) rather than in the liquid phase, and portions We derived three MCB and WCB from one initial
fetal skin tissue to look at variability of fresh tissue pro-of each cell bank were split between different vessels in
separate locations for security. cessing. The initial fetal skin tissue was divided into
three equivalent sections. Each section was treated as anAlthough very extensive data tracking is essential for
GMP records, for our laboratory cell banks we prepared independent tissue according to the procedure described
above. Protein concentration and mRNA level of MMP-a certificate of analysis for each cell bank, giving its
designation, number of ampoules prepared, date, tests 14, MMP-3, TIMP-3, and VEGF were measured at pas-
sage 3 in triplicate in each of the three independent cul-performed, specification, and results. Ampoules were la-
beled with the cell bank code and each ampoule individ- tures designated as A, B, and C. Protein concentration
was measured in fetal cell extract obtained by freeze–ually numbered. Logbooks were used to record all am-
poule movements including the initial deposit of the cell thaw cycles with Bradford Protein Assay (Biorad, CA,
USA) using albumin from bovine serum fraction V forbank and also each time an ampoule was removed,
whether for testing or for experimental purposes. These the standard curve. Total RNA was isolated from cultured
cells using the NucleoSpin, RNA II kit (Marchery-changes were signed and dated in the cell bank logbook.
Nagel, Du¨ren, Germany) as described by the manufac-
Safety Testing turer. One microgram of total RNA was reverse tran-
scribed using the 50 units of StratScript reverse transcript-The master cell bank (MCB) of one cell line destined
for clinical use was characterized and extensively tested ase enzyme (Stratagene, San Diego, CA, USA) in a
volume of 50 µl containing 1× first-strand buffer (Strata-in the GMP facilities of Bioreliance in Glascow, Scot-
land to demonstrate the absence of viruses (Fig. 1, MCB gene), 3 µl of random primers (100 ng/µl) (Promega,
Madison, WI, USA), 40 units of RNasin (Promega), andtesting). Testing requirements were based on those re-
quired for human diploid cells used for vaccine produc- 2 µl of dNTP mix 100 mM (Promega) as described by
the manufacturer. mRNA expression of matrix metallo-tion (33) and for cell substrates used for biotechnologi-
cal products (6). All the tests performed are listed in proteinase-3 (MMP-3), MMP-14, tissue inhibitor of met-
alloproteinase-3 (TIMP-3), vascular endothelial growthFigure 1.
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factor, and β-actin were measured by real-time PCR us- ferent concentrations could stimulate aged skin cell
growth and with higher concentrations to look at poten-ing TaqMan Gene Expression Assays (Applied Bio-
sytems). Measurements were performed in triplicates. tial toxicity (1–2 × 106 cells/extract).
Relative gene expressions were analyzed with the 2−∆∆CT
RESULTSmethod and normalized to β-actin gene.
Cell Banking
Life Span of Cell Lines With our fetal tissue we deviate from a conventional
The entire life span of each cell line was determined process of cell banking, which is usually started with an
to define limitations of cell bank usage. Cellular life ampoule of frozen cells. Our MCB was not from frozen
span was defined as the number of in vitro passages cells, but derived from the fresh fetal tissue itself. A
until the growth rate was reduced to 25% of the initial MCB of 50 ampoules of 5 million cells at passage 1
maximum growth rate. Three independent cell cultures could be established from each fetal skin biopsy. Each
(A, B, and C) were serially cultured in monolayer from ampoule of cells in the MCB was mixed to assure con-
passage 2 to 18. Each week using the previous passage, sistency and that each was identical. Ampoules of cells
three new plates with 3,000 or 6,000 cells per cm2 were from the MCB were then expanded by serial subculture
prepared for a total of 18 weeks. Cell number was manu- up to passage 2 and pooled for distribution into am-
ally counted after 7 days of culture for each passage. poules to form the WCB, for which vials were then used
Once the cell life had been determined for each fetal for specific research projects or preclinical trials. The
skin fibroblast cell line, some cells were retained to pro- WCB generated consisted of 50 ampoules each with 5
vide cells for testing beyond the production limit (ex- million cells in each one for each fetal tissue at passage
tended passage). These cells were stored as an “ex- 2 and 4, respectively (Fig. 1).
tended-life cell bank” and were tested to confirm that
Life Span of Fetal Cell Linesthey still possess the same characteristics as those from
the WCB with respect to karyology, morphology, iden- Actual cell counts were conducted each week with
tity, and biological activity. two media changes on triplicate plates of cells after 7
days of cell growth for two different initial concentra-
Consistency Between Biopsies of Different tions of cells: 3,000 and 6,000 cells/cm2. Each week us-
Tissue Donations ing the previous passage, three new plates with these
We derived master and working cell banks from four concentrations were prepared for a total of 18 weeks.
fetal donors (FS1, 14 weeks; FS2, 17 weeks; FS3, 13 For the concentration of 3,000 cells/cm2, stable popula-
weeks; FS4, 14 weeks) to investigate interindividual tions were seen up to passage 12 where cell number
variation possibilities at several gestational ages. Protein decreased to 25% of initial cell number. When cells
concentration was measured with the Bradford Assay were cultured at 6,000 cells/cm2, it was possible to con-
(Biorad) in fetal cell extract obtained by freeze–thaw tinue several additional passages to 17 where the growth
cycles. The concentration of basic fibroblast growth fac- was then reduced to 25% of the growth seen in early
tor (bFGF) was measured in fetal cell extract with the passages (Fig. 2). It is necessary to establish the most
human bFGF EIA Kit (Chemicon Internationale, CA, efficient cell life by using the minimum number of ini-
USA). tially seeded cells, which will permit the maximum pro-
mRNA expression of Midkine (neurite growth pro- duction of a finished product at the passages permitted
moting factor 2 NEGF2 or MDK), transforming growth (less than 2/3 the life of the cell line under specific con-
factor-β1 (TGF-β1), osteoprotegerin (OPG), pleio- ditions).
trophin (PTN), and β-actin were measured by real-time
Testing for Clinical and Research PurposesPCR as described above.
All of the tests listed in Figure 1 for MCB testing
Biological Activity of Fetal Cell Extracts will need to have a negative result to be cleared for fur-
ther use. There has to be absolute surety for the absenceAs an additional consistency test, the biological activ-
ity of the cells was tested. Fetal cell extract obtained as of contaminants, whether microbiological or viral, for a
product that is destined for clinical use. All passagesdescribed above was added to the culture medium of
aged adult skin cells (NP/CHFR, male, 76 years old). used for direct application will need to be batch tested
with specific criteria fulfilling a batch release record.The number of NP/CHFR skin cells was counted manu-
ally in triplicate using a hemocytometer and trypan blue These cell lines will also need to be checked routinely
for contamination just before application to the patient.exclusion for viability after 4 days of stimulation with
fetal cell extracts (concentrations ranging from 0 to 4 × Regarding research use, testing fetal cells that have been
banked in a WCB should have routine testing of myco-105 cells/extract) to determine if fetal cell extracts at dif-
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Figure 1. MCB and WCB processing with associated safety testing.
plasma and microbial contamination conducted every freeze–thaw extract of the three independent cell cul-
tures (A, B, C) at 3,000 cells/cm2 from passage 1 to 11.month on the cell lines in use (Fig. 1, WCB testing).
The range of mean protein concentration was 1.7 ± 0.2
Consistency of Tissue Processing µg/µl at passage 0 and 3.9 ± 0.5 µg/µl at passage 5.
When looking at the variability between the three inde-From the original fetal tissue, three different cultures
were developed and each of these cultures was tested in pendent cultures (A, B, and C), fold difference in protein
concentration between A, B, and C was the lowest attriplicate for protein concentration and gene expression
(Fig. 3). Protein concentration was measured in the passage 0 (1.1-fold difference) and the highest at pas-
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Figure 2. Cellular life span of fetal cells in culture. Number of fetal skin cells counted at each
passage up to 18 passages for each of three independent cultures from the same tissue at 3,000 or
6,000 cells/cm2 initially seeded.
sage 10 (1.4-fold difference). No significant differences 0.4; FS3: 4.5 ± 0.2 ; FS4: 4.0 ± 0.2 µg/µl) as well as β-
FGF concentration, normalized to total protein concen-were noted throughout the cell handling for the same
number of cells per extraction. In addition, the three in- tration. mRNA expression of MDK, PTN, TGF-β1, and
OPG had a similar level among the four different celldependent cultures showed relatively consistent mRNA
level of genes involved in skin regeneration, MMP-14, cultures. The maximal fold differences in gene expres-
sion between the four cell cultures were 2.2, 2.2, 1.5 andMMP-3, TIMP-3, and VEGF, with maximal fold differ-
ence between the three independent cultures of 1.4, 1.9, 3.1, respectively, for MDK, PTN, TGF-β1 and OPG
(Fig. 4).2.1 and 1.4, respectively.
Consistency Between Tissues of Different Donors Biological Activity
When added to aged fibroblasts, NP/CHFR, in cellCell cultures derived from four biopsies from differ-
ent tissue donations yielded 4.1 (FS1), 4.4 (FS2), 2.9 culture, fetal cell extracts had a stimulatory effect on the
cell growth of NP/CHFR cells (Fig. 5). The effect was(FS3), and 3.6 (FS4) million cells at passage 4. In addi-
tion, protein concentration measured in extracts pro- dose dependent, with a 2.6 increase in growth stimula-
tion of NP/CHFR cells seen with fetal extracts comparedcessed by freeze–thawing three times was not different
among the four cell cultures (FS1: 4.2 ± 0.7; FS2: 4.6 ± to controls where only buffer was added. At higher
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doses, the growth stimulation remained at the maximum therapy application for skin TEP. Clinical uses have ex-
tended significantly for a wide variety of indications in-height seen. Much higher doses of fetal cell extract—
five times what was used in experimentation for growth cluding burns, acute and chronic wounds, skin loss, sur-
gical wounds, and bullous diseases (5,11,12,14,25,28).stimulation (2 × 106 cells/extract)—were necessary for
some toxicity (20–30%) of target cells and this may This means that stringent controls and testing are neces-
sary to ensure proper safety (6).have also been due, in part, to the increased volume nec-
essary to deliver this dilution of the extract. For maximum security, it would be best to have ex-
tensive testing on cell lines used in preclinical studies.
DISCUSSION Thus, fetal cells have a major advantage because exten-
sive material for therapeutic usage can be developedFetal skin cells show qualities required for the estab-
lishment of a cell bank to be used for TEP and medicinal from only one organ donation. However, due to the im-
peding costs, cell banks destined only for research pur-products. The life span and the proliferation rate of the
cells allowed to build a MCB of 50 ampoules containing poses are difficult to test thoroughly.
Until now, there have been no reported biopharma-4–5 million cells each from only one organ donation.
Then each ampoule from the MCB can be derived into ceuticals derived from continuous cell cultures that have
been implicated in the transmission of infectious agentsa WCB to be used for clinical or research purposes.
MCB and WCB have been prepared from fetal skin tis- to humans. Most sources of contamination are adventi-
tious, which means that the contamination is introducedsue in short periods of time compared to other primary
cells, which saves not only time but is interesting finan- from an external source such as the medium, trypsin, or
serum used in the culture process. Several points of in-cially because GMP sterile facilities are usually rented
by the day. Cell banking offers advantages for safe cell terest in cell culture that are to be used in preclinical
Figure 3. Consistency of the processing of tissue. Protein concentration and RT PCR of specific genes in the three independent
cultures A, B, and C derived from one biopsy.
682 QUINTIN ET AL.
Figure 4. Cell growth, protein concentrations, and fibroblast growth factor and RT-PCR of specific genes in different donors of
fetal cells.
and clinical trials are that any animal products used in rum production and a guaranteed traceability for each
bottle that is destined for cell cultures for preclinical andthe cell culture process, such as bovine serum and tryp-
sin, should be virus tested and transmissible spongiform clinical usage. In addition, because of concerns about
the transmission of bovine viruses it is recommendedencephalopaties (TSE) certified (7). Reported cases of
bovine spongiform encephalopathy (BSE) have made it that the serum be inactivated (e.g., by gamma irradia-
tion) prior to use (7). Stringent control of potential viralnecessary for stringent testing of serum. As only New
Zealand or Australia have no reported BSE, these coun- contamination is particularly important with this product
as it is not subject to any purification steps and it is nottries have interesting serum for research and clinical
purposes (21). Other companies (i.e., Hyclone, Gibco) certain what, if any, viral inactivation steps may be ap-
plied (7). If EDTA alone can be used for cell detach-assure the contained and well-maintained herds for se-
Figure 5. Biological activity of fetal skin extracts. Number of aged skin cells (NP/CHFR) activated as a function of various
concentrations of fetal skin cell extract after 4 days of culture.
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ment, it would be beneficial to avoid the use of trypsin in the development. Cell choice for TEP is of utmost
importance, and progress to assure the consistency willbecause of viral safety concerns or the trypsin will need
separate testing. In addition, the use of antibiotics in the be necessary before allowing preclinical trials. Fetal cell
research was seriously impeded in the 1980s. Becausemedium is not an acceptable practice and should also be
avoided. Thus, it is necessary to test both of the cell academic programs could not easily continue fundamen-
tal research on fetal cells, the means to establish betterbanks that have been produced but an increased testing
should be emphasized on the MCB. primary cell cultures and study consistent processing
lost at least a decade of advancement. It was researchOnce the MCB has been thoroughly screened and
shown negative for all of the necessary testing, a less on stem cells that brought cell choice back into the cen-
ter of study for TEP (3,10,15,27,30,31). Using only onestringent testing platform should be established for the
WCB that includes the isoenzyme assay assuring the fetal organ donation, it is possible to develop extensive
MCB and WCB. Fetal cells, as already differentiatedidentity, sterility, and mycoplasma. As extensive viral
safety testing was performed on the mother donor when lineage, need low nutritional requirements (i.e., no
feeder layers or external growth factors) to establish atissue was donated and at a 3-month interval to assure
there was not sero-conversion; this provides the first se- fully defined consistent cell bank and can easily be as-
sessed for safety, assuring an interesting cell choice forcurity for laboratory employees. In vitro testing should
be concluded to ensure no adventitious agents were in- TEP.
troduced during the preparation of the bank either from ACKNOWLEDGMENTS: This study was supported by grants
the medium and its associated constituents used in the from the Swiss National Science Foundation (PNR 46), the
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